98%
921
2 minutes
20
is an important fungus that produces aspartic proteases suitable for cheese processing. In this study, a novel aspartic protease gene () was cloned from CAU432 and expressed in . The amino acid sequence of RmproB shared the highest identity of 58.2% with the saccharopepsin PEP4 from . High protease activity of 1242.2 U/mL was obtained through high density fermentation in 5 L fermentor. RmproB showed the optimal activity at pH 2.5 and 40 °C, respectively. It was stable within pH 1.5-6.5 and up to 45 °C. RmproB exhibited broad substrate specificity and had values of 3.16, 5.88, 5.43, and 1.56 mg/mL for casein, hemoglobin, myoglobin, and bovine serum albumin, respectively. RmproB also showed remarkable milk-clotting activity of 3894.1 SU/mg and identified the cleavage of Lys21-Ile22, Leu32-Ser33, Lys63-Pro64, Leu79-Ser80, Phe105-Met106, and Asp148-Ser149 bonds in κ-casein. Moreover, duck hemoglobin was hydrolyzed by RmproB to prepare angiotensin-I-converting enzyme (ACE) inhibitory peptides with high ACE-inhibitory activity (IC of 0.195 mg/mL). The duck hemoglobin peptides were further produced at kilo-scale with a yield of 62.5%. High-level expression and favorable biochemical characterization of RmproB make it a promising candidate for cheese processing and production of ACE-inhibitory peptides.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701012 | PMC |
http://dx.doi.org/10.3390/foods10122949 | DOI Listing |
Biomater Sci
September 2025
School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia.
The increasing use of blood-contacting medical devices has brought about significant advancements in patient care, yet it also presents challenges such as thrombus formation and infection risks. Surface coatings play a vital role in mitigating these side effects, enhancing the safety and effectiveness of such devices. In this study, we introduced a novel coating employing poly(aspartic acid) (PASP), which can be easily applied through various modification pathways.
View Article and Find Full Text PDFMol Ther Methods Clin Dev
June 2025
Precision Safety, Pharma Product Development, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
Adeno-associated virus (AAV) vectors are widely used in gene therapy, particularly for liver-targeted treatments. However, predicting human-specific outcomes, such as transduction efficiency and hepatotoxicity, remains challenging. Reliable models are urgently needed to bridge the gap between preclinical studies and clinical applications.
View Article and Find Full Text PDFBiomed Rep
November 2025
College of Public Health, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China.
flavones (PRFs), bioactive components derived from the plant, exhibit anti-inflammatory and anti-tumor properties. However, their therapeutic potential for bladder cancer remains poorly understood. The present study aimed to investigate the anti-tumor effects and molecular mechanisms underlying the effects of PRF on human bladder cancer T24 cells.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Institut de Biologie de l'Ecole Normale Supérieure, Ecole Normale Supérieure, Université Paris Sciences et Lettres, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Paris 75005, France.
Excitatory glycine receptors (eGlyRs), composed of the glycine-binding NMDA receptor subunits GluN1 and GluN3A, have recently emerged as a novel neuronal signaling modality that challenges the traditional view of glycine as an inhibitory neurotransmitter. Unlike conventional GluN1/GluN2 NMDARs, the distribution and role of eGlyRs remain poorly understood. Here, we show that eGlyRs are highly enriched in the ventral hippocampus (VH) and confer distinct properties on this brain region.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh-Punjab 147301, India.
Alcoholic fatty liver disease (AFLD) is a leading cause of chronic liver disease worldwide, contributing to significant morbidity and mortality. Despite its growing prevalence, no FDA-approved pharmacological treatments exist, leaving lifestyle modifications as the primary intervention. AFLD pathogenesis involves a complex interplay of lipid accumulation, oxidative stress, insulin resistance, and inflammation, highlighting the need for innovative therapeutic approaches.
View Article and Find Full Text PDF